COMP <GO>
TVTX vs UNH // FREE CASH FLOW YIELD
Travere Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: TVTX 4
— UNH 9
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $50.39 (-0.36%) • MKT CAP: $4.77B
fcf-yield
0.33%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | TVTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 11.47% | -24.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.33% | 6.48% | -6.15 | UNH | /fcf-yield <GO> |
| Operating Margin | -12.80% | 4.82% | -17.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.20% | 3.14% | -8.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | 6.46% | +104.04 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.44 | 3.12 | +0.32 | TVTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 56.0 | -20.61 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | TVTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 17.1x | +0.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $364.66B | -$359.89B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | UNH REV | TVTX GROSS % | UNH GROSS % | TVTX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $447.57B | 97.9% | 88.7% | $15.7M | $16.07B |
| FY 2024 | $233.2M | $400.28B | 96.7% | 88.3% | -$248.0M | $20.70B |
| FY 2023 | $145.2M | $371.62B | 44.0% | 89.6% | -$286.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
UNH // BETA 0.33